0001802806-23-000013.txt : 20231215
0001802806-23-000013.hdr.sgml : 20231215
20231215164904
ACCESSION NUMBER: 0001802806-23-000013
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
EFFECTIVENESS DATE: 20231215
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: KAZIA THERAPEUTICS LTD
CENTRAL INDEX KEY: 0001075880
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: C3
FISCAL YEAR END: 0630
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-499912
FILM NUMBER: 231491058
BUSINESS ADDRESS:
STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24,
STREET 2: 300 BARANGAROO AVENUE
CITY: SYDNEY NSW
STATE: C3
ZIP: 2000
BUSINESS PHONE: 01161298780088
MAIL ADDRESS:
STREET 1: THREE INTERNATIONAL TOWERS LEVEL 24,
STREET 2: 300 BARANGAROO AVENUE
CITY: SYDNEY NSW
STATE: C3
ZIP: 2000
FORMER COMPANY:
FORMER CONFORMED NAME: NOVOGEN LTD
DATE OF NAME CHANGE: 19981228
D
1
primary_doc.xml
X0708
D
LIVE
0001075880
KAZIA THERAPEUTICS LTD
THREE INTERNATIONAL TOWERS LEVEL 24,
300 BARANGAROO AVENUE
SYDNEY NSW
C3
AUSTRALIA
2000
01161298780088
AUSTRALIA
NOVOGEN LTD
Corporation
true
John
Friend
THREE INTERNATIONAL TOWERS LEVEL 24
300 BARANGAROO AVENUE
SYNDEY NSW
C3
AUSTRALIA
2000
Executive Officer
Director
Karen
Krumeich
THREE INTERNATIONAL TOWERS LEVEL 24
300 BARANGAROO AVENUE
SYNDEY NSW
C3
AUSTRALIA
2000
Executive Officer
Bryce
Carmine
THREE INTERNATIONAL TOWERS LEVEL 24
300 BARANGAROO AVENUE
SYNDEY NSW
C3
AUSTRALIA
2000
Director
Steven
Coffey
THREE INTERNATIONAL TOWERS LEVEL 24
300 BARANGAROO AVENUE
SYNDEY NSW
C3
AUSTRALIA
2000
Director
Ebru
Davidson
THREE INTERNATIONAL TOWERS LEVEL 24
300 BARANGAROO AVENUE
SYNDEY NSW
C3
AUSTRALIA
2000
Director
Biotechnology
Decline to Disclose
- 06b
false
2023-12-05
false
true
true
false
0
H.C.WAINWRIGHT & CO., LLC
375
None
None
430 PARK AVENUE
4TH FLOOR
NEW YORK
NY
NEW YORK
10022
NY
NEW YORK
false
2000000
2000000
0
false
1
0
true
0
In connection with the registered direct offering concurrent with this private placement, the placement agent received warrants to purchase up to 311,111 American Depoistary Shares ("ADSs") exercisable at $0.5625 per ADS.
0
false
KAZIA THERAPEUTICS LTD
/s/ Karen Krumeich
Karen Krumeich
CFO
2023-12-15